PT3119752T - Compostos 3,4-diamino-6-cloropirazina-2-carboxamida para o tratamento de doenças mediadas por enac - Google Patents

Compostos 3,4-diamino-6-cloropirazina-2-carboxamida para o tratamento de doenças mediadas por enac

Info

Publication number
PT3119752T
PT3119752T PT157133398T PT15713339T PT3119752T PT 3119752 T PT3119752 T PT 3119752T PT 157133398 T PT157133398 T PT 157133398T PT 15713339 T PT15713339 T PT 15713339T PT 3119752 T PT3119752 T PT 3119752T
Authority
PT
Portugal
Prior art keywords
chloropyrazine
diamino
treatment
mediated diseases
carboxamide compounds
Prior art date
Application number
PT157133398T
Other languages
English (en)
Inventor
Elisabeth Berglund Susanne
Connolly Stephen
Hemmerling Martin
Hossain Nafizal
Kristoffersson Anna
Rune Michael Lundkvist Johan
Nikitidis Grigorios
Elisabeth Ripa Lena
Shamovsky Igor
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PT3119752T publication Critical patent/PT3119752T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT157133398T 2014-03-18 2015-03-17 Compostos 3,4-diamino-6-cloropirazina-2-carboxamida para o tratamento de doenças mediadas por enac PT3119752T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461954674P 2014-03-18 2014-03-18

Publications (1)

Publication Number Publication Date
PT3119752T true PT3119752T (pt) 2018-07-24

Family

ID=52780553

Family Applications (1)

Application Number Title Priority Date Filing Date
PT157133398T PT3119752T (pt) 2014-03-18 2015-03-17 Compostos 3,4-diamino-6-cloropirazina-2-carboxamida para o tratamento de doenças mediadas por enac

Country Status (38)

Country Link
US (3) US9873678B2 (pt)
EP (1) EP3119752B1 (pt)
JP (1) JP6502469B2 (pt)
KR (1) KR102296041B1 (pt)
CN (1) CN106103423B (pt)
AP (1) AP2016009447A0 (pt)
AR (1) AR099790A1 (pt)
AU (1) AU2015233195B2 (pt)
CA (1) CA2941807C (pt)
CL (1) CL2016002303A1 (pt)
CR (1) CR20160479A (pt)
CY (1) CY1120509T1 (pt)
DK (1) DK3119752T3 (pt)
DO (1) DOP2016000232A (pt)
EA (1) EA029952B1 (pt)
ES (1) ES2679618T3 (pt)
GT (1) GT201600190A (pt)
HR (1) HRP20181123T1 (pt)
HU (1) HUE039425T2 (pt)
IL (1) IL247610B (pt)
LT (1) LT3119752T (pt)
ME (1) ME03056B (pt)
MX (1) MX368577B (pt)
NI (1) NI201600134A (pt)
NZ (1) NZ724063A (pt)
PE (1) PE20170205A1 (pt)
PH (1) PH12016501808A1 (pt)
PL (1) PL3119752T3 (pt)
PT (1) PT3119752T (pt)
RS (1) RS57487B1 (pt)
SG (1) SG11201607751SA (pt)
SI (1) SI3119752T1 (pt)
SV (1) SV2016005278A (pt)
TR (1) TR201810207T4 (pt)
TW (1) TWI687410B (pt)
UY (1) UY36034A (pt)
WO (1) WO2015140527A1 (pt)
ZA (1) ZA201607136B (pt)

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3577418A (en) 1969-02-12 1971-05-04 Merck & Co Inc Pyrazinamide derivatives and processes for their preparation
US3573306A (en) 1969-03-05 1971-03-30 Merck & Co Inc Process for preparation of n-substituted 3,5-diamino-6-halopyrazinamides
FI820266L (fi) 1981-02-02 1982-08-03 Ici Plc Alkanolaminderivater
EP0086564B1 (en) 1982-01-29 1985-11-21 Imperial Chemical Industries Plc Alkanolamine derivatives
GB8810933D0 (en) 1987-05-26 1988-06-15 Ici America Inc Heterocyclic compounds
GB8810934D0 (en) 1987-05-26 1988-06-15 Ici America Inc Amides
US4803206A (en) 1988-03-07 1989-02-07 Schering Corporation Antihypertensive acylpyrazines
GB8812342D0 (en) 1988-05-25 1988-06-29 Ici America Inc Bicyclic compounds
GB8812343D0 (en) 1988-05-25 1988-06-29 Ici America Inc Amino compounds
US6403587B1 (en) 1997-02-26 2002-06-11 Pfizer Inc. Heteroaryl-hexanoic acid amide derivatives, their preparation and their use as selective inhibitors of MIP-1-α binding to its CCR 1 receptor
GB9930557D0 (en) 1999-12-23 2000-02-16 Rolic Ag Optically active materials
CA2781858C (en) 2000-05-12 2015-03-31 Genzyme Corporation Modulators of tnf-.alpha. signaling
EA200400648A1 (ru) 2001-11-08 2005-04-28 Элан Фармасьютикалз, Инк. N, n'-замещенные производные 1,3-диамино-2-гидроксипропана
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20040087571A1 (en) 2002-10-30 2004-05-06 Pfizer Inc Methods of using CCR1 antagonists as immunomodulatory agents
EP1581499A1 (en) 2002-12-20 2005-10-05 Pfizer Products Inc. Microsomal triglyceride transfer protein inhibitors
US6903105B2 (en) 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
WO2006044381A2 (en) 2004-10-13 2006-04-27 University Of Connecticut Cannabinergic lipid ligands
GB0511065D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0526240D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
MX2009009304A (es) 2007-03-01 2009-11-18 Novartis Ag Inhibidores de cinasa pim y metodos para su uso.
ES2361595T3 (es) 2007-05-07 2011-06-20 Novartis Ag Compuestos orgánicos.
PT2444120T (pt) 2007-12-10 2018-01-03 Novartis Ag Análogos da amilorida espirocíclicos como bloqueadores de enac
EP2219646A4 (en) 2007-12-21 2010-12-22 Univ Rochester METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS
KR20110011621A (ko) 2008-05-13 2011-02-08 노파르티스 아게 3,5―디아미노―6―클로로―피라진―2―카르복실산 유도체 및 기도 질환의 치료를 위한 상피 나트륨 채널 차단제로서의 이들의 용도
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
US8236808B2 (en) * 2008-06-10 2012-08-07 Novartis Ag Pyrazine derivatives as ENAC blockers
WO2011028740A1 (en) * 2009-09-03 2011-03-10 Glaxo Group Limited ENaC BLOCKERS
WO2011079087A1 (en) 2009-12-23 2011-06-30 Glaxo Group Limited Enac blockers
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
WO2013192517A2 (en) 2012-06-21 2013-12-27 Whitehead Institute For Biomedical Research Compounds for treating infectious diseases
CN105073717B (zh) 2012-12-17 2018-05-22 帕里昂科学公司 可用于治疗由黏膜水化不足造成的疾病的氯-吡嗪甲酰胺衍生物
AU2013363215B2 (en) 2012-12-17 2018-03-01 Parion Sciences, Inc. 3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
ES2674665T3 (es) 2012-12-17 2018-07-03 Parion Sciences, Inc. Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida

Also Published As

Publication number Publication date
NZ724063A (en) 2018-02-23
US10954211B2 (en) 2021-03-23
AU2015233195A1 (en) 2016-09-22
JP2017512830A (ja) 2017-05-25
KR102296041B1 (ko) 2021-08-30
HRP20181123T1 (hr) 2018-09-21
EA029952B1 (ru) 2018-06-29
EA201691641A1 (ru) 2017-02-28
NI201600134A (es) 2017-03-13
IL247610A0 (en) 2016-11-30
TR201810207T4 (tr) 2018-08-27
DK3119752T3 (en) 2018-07-30
GT201600190A (es) 2019-07-29
HUE039425T2 (hu) 2018-12-28
US10336725B2 (en) 2019-07-02
UY36034A (es) 2015-09-30
CN106103423A (zh) 2016-11-09
US20170107195A1 (en) 2017-04-20
SI3119752T1 (en) 2018-08-31
AR099790A1 (es) 2016-08-17
TW201620880A (zh) 2016-06-16
PE20170205A1 (es) 2017-04-06
US20180162838A1 (en) 2018-06-14
TWI687410B (zh) 2020-03-11
KR20160127135A (ko) 2016-11-02
CL2016002303A1 (es) 2017-01-13
CR20160479A (es) 2017-02-24
MX2016011681A (es) 2016-10-28
JP6502469B2 (ja) 2019-04-17
SG11201607751SA (en) 2016-10-28
MX368577B (es) 2019-10-08
ES2679618T3 (es) 2018-08-29
CN106103423B (zh) 2019-12-06
WO2015140527A1 (en) 2015-09-24
US20190330187A1 (en) 2019-10-31
IL247610B (en) 2019-05-30
LT3119752T (lt) 2018-08-10
PL3119752T3 (pl) 2018-09-28
CA2941807C (en) 2023-03-07
CY1120509T1 (el) 2019-07-10
EP3119752A1 (en) 2017-01-25
AP2016009447A0 (en) 2016-09-30
ME03056B (me) 2018-10-20
RS57487B1 (sr) 2018-10-31
PH12016501808B1 (en) 2017-01-09
DOP2016000232A (es) 2016-10-16
CA2941807A1 (en) 2015-09-24
EP3119752B1 (en) 2018-05-16
US9873678B2 (en) 2018-01-23
SV2016005278A (es) 2016-11-30
AU2015233195B2 (en) 2017-04-20
PH12016501808A1 (en) 2017-01-09
ZA201607136B (en) 2018-04-25

Similar Documents

Publication Publication Date Title
HK1244280B (zh) 用於治療感染性疾病的吡嗪化合物
IL264049A (en) Compounds, preparations and methods for treating the disease
IL264156A (en) Compounds, preparations and methods for treating the disease
HK1244485A1 (zh) 用於治療神經母細胞瘤的組合物
IL249502A0 (en) Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of protein-associated diseases
HK1232220A1 (zh) 用於治療心血管疾病的 -苄基異喹啉衍生物
EP3169405A4 (en) Methods, compounds, and compositions for the treatment of musculoskeletal diseases
IL259381B (en) Miravegron for the treatment of retinal diseases
SG11201703330YA (en) Iminosugars useful for the treatment of viral diseases
HRP20181123T1 (hr) Spojevi 3,4-diamino-6-kloropirazin-2-karboksamida za liječenje bolesti posredovanih s enac
SI3903774T1 (sl) N,N-bis-2-merkaptoetil izoftalamid za zdravljenje nevrodegenerativnih bolezni
PL3164110T3 (pl) Kompozycje farmaceutyczne do leczenia łuszczycy
ZA201704589B (en) Compounds for the treatment of cancer